Edition:
United Kingdom

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

44.98USD
19 Oct 2018
Change (% chg)

-- (--)
Prev Close
$44.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
233,405
52-wk High
$82.68
52-wk Low
$33.06

Chart for

About

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the... (more)

Overall

Beta: 2.67
Market Cap(Mil.): $1,444.21
Shares Outstanding(Mil.): 25.69
Dividend: --
Yield (%): --

Financials

  ESPR.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -5.77 -- --
ROI: -61.42 0.21 14.27
ROE: -61.71 1.17 15.99

Esperion's combo therapy lowers cholesterol level by 35 percent, shares surge

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

27 Aug 2018

UPDATE 1- Esperion's combo therapy lowers cholesterol level by 35 pct, shares surge

Aug 27 Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

27 Aug 2018

Esperion's cholesterol drug safe, effective in new late-stage study

May 23 Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment's efficacy.

23 May 2018

BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID

02 May 2018

BRIEF-Esperion Posts Qtrly Loss Per Share $1.73

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

02 May 2018

Earnings vs. Estimates